Role of monoamine-oxidase-A-gene variation in the development of glioblastoma in males: a case control study.


Journal

Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 01 08 2019
accepted: 16 09 2019
pubmed: 27 9 2019
medline: 5 6 2020
entrez: 27 9 2019
Statut: ppublish

Résumé

The Mono-amine oxidase-A (MAO-A) enzyme is involved in the degradation and regulation of catecholamines such as serotonin, dopamine, epinephrine and nor-epinephrine. Preclinical studies suggest that this enzyme may contribute to an environment favorable for growth of malignant glioma. The MAO-A gene is located on the X-chromosome and has at least one functional genetic polymorphism. The aim of the present study was to explore possible effects of MAO-A genotype on development of glioblastoma in males. Genotypes for 437 glioma cases and 876 population-based controls from the Swedish Glioma International Case-Control study (GICC) were compared. We analyzed the germline DNA using the Illumina Oncoarray. We selected seven single nucleotide polymorphisms (SNPs) located in the MAO-A gene, and imputed genotypes based on data from the 1000 genomes project. We used 1579 male glioblastoma cases and 1875 controls comprising the whole GICC cohort for subsequent validation of findings. The rs144551722 SNP was a significant predictor of development of glioblastoma in males (p-value = 0.0056) but not in females even after correction for multiple testing. We conducted haplotype analysis to confirm an association between MAO-A gene and risk of glioblastoma (p-value = 0.016). We found similar results in the validation sample. These results suggest the possibility of a role for the MAO-A enzyme and the MAO-A gene in the development of glioblastoma in males.

Sections du résumé

BACKGROUND BACKGROUND
The Mono-amine oxidase-A (MAO-A) enzyme is involved in the degradation and regulation of catecholamines such as serotonin, dopamine, epinephrine and nor-epinephrine. Preclinical studies suggest that this enzyme may contribute to an environment favorable for growth of malignant glioma. The MAO-A gene is located on the X-chromosome and has at least one functional genetic polymorphism. The aim of the present study was to explore possible effects of MAO-A genotype on development of glioblastoma in males.
METHODS METHODS
Genotypes for 437 glioma cases and 876 population-based controls from the Swedish Glioma International Case-Control study (GICC) were compared. We analyzed the germline DNA using the Illumina Oncoarray. We selected seven single nucleotide polymorphisms (SNPs) located in the MAO-A gene, and imputed genotypes based on data from the 1000 genomes project. We used 1579 male glioblastoma cases and 1875 controls comprising the whole GICC cohort for subsequent validation of findings.
RESULTS RESULTS
The rs144551722 SNP was a significant predictor of development of glioblastoma in males (p-value = 0.0056) but not in females even after correction for multiple testing. We conducted haplotype analysis to confirm an association between MAO-A gene and risk of glioblastoma (p-value = 0.016). We found similar results in the validation sample.
CONCLUSIONS CONCLUSIONS
These results suggest the possibility of a role for the MAO-A enzyme and the MAO-A gene in the development of glioblastoma in males.

Identifiants

pubmed: 31556016
doi: 10.1007/s11060-019-03294-w
pii: 10.1007/s11060-019-03294-w
pmc: PMC6856259
doi:

Substances chimiques

Monoamine Oxidase EC 1.4.3.4
monoamine oxidase A, human EC 1.4.3.4.

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

287-294

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA139020
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA139020
Pays : United States

Investigateurs

Margaret R Wrensch (MR)
Sara H Olson (SH)
Michael E Scheurer (ME)
Dora Il'yasova (D)
Daniel Lachance (D)
Georgina N Armstrong (GN)
Lucie S McCoy (LS)
Ching C Lau (CC)
Elizabeth B Claus (EB)
Jill S Barnholtz-Sloan (JS)
Joellen Schildkraut (J)
Francis Ali-Osman (F)
Siegal Sadetzki (S)
Christoffer Johansen (C)
Richard S Houlston (RS)
Robert B Jenkins (RB)
Jonine L Bernstein (JL)
Ryan T Merrell (RT)
Faith G Davis (FG)
Rose Lai (R)
Sanjay Shete (S)
Christopher I Amos (CI)
Beatrice S Melin (BS)
Melissa L Bondy (ML)

Références

G3 (Bethesda). 2011 Nov;1(6):457-70
pubmed: 22384356
Nat Neurosci. 2004 Jul;7(7):726-35
pubmed: 15195095
Science. 1993 Oct 22;262(5133):578-80
pubmed: 8211186
Hum Genet. 1998 Sep;103(3):273-9
pubmed: 9799080
Eur J Cancer. 2012 Jul;48(10):1532-42
pubmed: 22227039
Psychiatry Res. 2011 Feb 28;185(3):382-6
pubmed: 20850185
Neuro Oncol. 2018 Jul 5;20(8):1014-1025
pubmed: 29126252
Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6269-74
pubmed: 16569698
J Neural Transm (Vienna). 2018 Nov;125(11):1553-1566
pubmed: 30259128
Science. 2002 Aug 2;297(5582):851-4
pubmed: 12161658
Nat Genet. 2012 Jul 22;44(8):955-9
pubmed: 22820512
Exp Neurol. 2009 Oct;219(2):543-52
pubmed: 19619535
Biol Psychiatry. 2006 Feb 15;59(4):334-40
pubmed: 16202396
Hum Mol Genet. 1999 Apr;8(4):621-4
pubmed: 10072430
Nature. 2004 Nov 18;432(7015):396-401
pubmed: 15549107
Am J Epidemiol. 2016 Jan 15;183(2):85-91
pubmed: 26656478
PLoS Genet. 2009 Jun;5(6):e1000529
pubmed: 19543373
Genomics. 1989 May;4(4):552-9
pubmed: 2744764
Neuroscience. 1999;89(4):999-1002
pubmed: 10362289
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Aug 1;69:101-11
pubmed: 26964906
Am J Med Genet B Neuropsychiatr Genet. 2007 Mar 5;144B(2):159-64
pubmed: 17034017
Biol Psychiatry. 2006 Jan 15;59(2):121-7
pubmed: 16125147
J Clin Invest. 2014 Jul;124(7):2891-908
pubmed: 24865426
Sci Rep. 2018 May 9;8(1):7352
pubmed: 29743610
Neuropsychopharmacology. 2008 Jan;33(2):425-30
pubmed: 17429405
Cancer Res. 2004 Aug 15;64(16):5551-5
pubmed: 15313889
Oncotarget. 2016 Jun 14;7(24):37043-37053
pubmed: 27175595
Nature. 2018 Aug;560(7717):243-247
pubmed: 30069053
Biol Psychiatry. 2012 Feb 15;71(4):350-7
pubmed: 22030358
Eur J Neurosci. 2004 Jul;20(2):575-9
pubmed: 15233767
J Biol Chem. 2006 Jul 28;281(30):21512-25
pubmed: 16728402
Nucleic Acids Res. 2018 Jan 4;46(D1):D802-D808
pubmed: 29092050
Nat Genet. 2017 May;49(5):789-794
pubmed: 28346443
Nat Methods. 2011 Dec 04;9(2):179-81
pubmed: 22138821
Oncotarget. 2016 Mar 22;7(12):13842-53
pubmed: 26871599
Clin Cancer Res. 2008 Apr 15;14(8):2502-10
pubmed: 18413843

Auteurs

Rickard L Sjöberg (RL)

Department of Clinical Science, Neuroscience, Umeå University, Umeå, Sweden. Rickard.sjoberg@umu.se.
Department of Neurosurgery, University Hospital of Northern Sweden, 901 85, Umeå, Sweden. Rickard.sjoberg@umu.se.

Wendy Yi-Ying Wu (WY)

Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.

Anna M Dahlin (AM)

Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.

Spiridon Tsavachidis (S)

Department of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.

Melissa L Bondy (ML)

Department of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.

Beatrice Melin (B)

Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH